RxDoctor Payments Data

Thomas Johnson, MD

Family Medicine · Jamestown, KYNPI 1821096421

Payments from drug & device makers

$8,998in general payments, 2019–2025

Across 566 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Pfizer$985
  • GSK$867
  • Lilly USA, LLC$472
  • Novo Nordisk$392
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,93699%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,998 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$159,448
Medicare patients
306
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$95,864
EliquisApixaban75$87,253
JardianceEmpagliflozin47$67,006
MounjaroTirzepatide45$44,378
OzempicSemaglutide37$42,141
XareltoRivaroxaban28$34,401
JanuviaSitagliptin Phosphate22$33,637
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$30,937
FarxigaDapagliflozin Propanediol26$25,141
MyrbetriqMirabegron14$19,116
LinzessLinaclotide19$18,319
RybelsusSemaglutide17$18,120
VascepaIcosapent Ethyl36$17,869
Spiriva HandihalerTiotropium Bromide18$15,297
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen521$14,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$867$95,86499 claims
PfizerEliquis, Dilantin$985$91,31692 claims
Boehringer IngelheimJardiance, Combivent Respimat$206$72,20258 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,081$65,15291 claims
Novo NordiskOzempic, Rybelsus$392$60,26154 claims
Lilly USA, LLCMounjaro$472$44,37845 claims
MerckJanuvia, Belsomra$78$39,23035 claims
Johnson & JohnsonXarelto$239$34,40128 claims
AbbVieLinzess, Synthroid$1,073$24,036100 claims
Astellas Pharma US IncMyrbetriq$116$19,11614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Jamestown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →